670 related articles for article (PubMed ID: 30826182)
1. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.
Mann JR; Gleixner AM; Mauna JC; Gomes E; DeChellis-Marks MR; Needham PG; Copley KE; Hurtle B; Portz B; Pyles NJ; Guo L; Calder CB; Wills ZP; Pandey UB; Kofler JK; Brodsky JL; Thathiah A; Shorter J; Donnelly CJ
Neuron; 2019 Apr; 102(2):321-338.e8. PubMed ID: 30826182
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death.
Gasset-Rosa F; Lu S; Yu H; Chen C; Melamed Z; Guo L; Shorter J; Da Cruz S; Cleveland DW
Neuron; 2019 Apr; 102(2):339-357.e7. PubMed ID: 30853299
[TBL] [Abstract][Full Text] [Related]
3. Optogenetic TDP-43 nucleation induces persistent insoluble species and progressive motor dysfunction in vivo.
Otte CG; Fortuna TR; Mann JR; Gleixner AM; Ramesh N; Pyles NJ; Pandey UB; Donnelly CJ
Neurobiol Dis; 2020 Dec; 146():105078. PubMed ID: 32927062
[TBL] [Abstract][Full Text] [Related]
4. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
Hayes LR; Kalab P
Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
[TBL] [Abstract][Full Text] [Related]
5. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
Gao J; Wang L; Yan T; Perry G; Wang X
Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
[TBL] [Abstract][Full Text] [Related]
6. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
[TBL] [Abstract][Full Text] [Related]
7. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy.
Chew J; Cook C; Gendron TF; Jansen-West K; Del Rosso G; Daughrity LM; Castanedes-Casey M; Kurti A; Stankowski JN; Disney MD; Rothstein JD; Dickson DW; Fryer JD; Zhang YJ; Petrucelli L
Mol Neurodegener; 2019 Feb; 14(1):9. PubMed ID: 30767771
[TBL] [Abstract][Full Text] [Related]
8. TDP-43 stabilizes G3BP1 mRNA: relevance to amyotrophic lateral sclerosis/frontotemporal dementia.
Sidibé H; Khalfallah Y; Xiao S; Gómez NB; Fakim H; Tank EMH; Di Tomasso G; Bareke E; Aulas A; McKeever PM; Melamed Z; Destroimaisons L; Deshaies JE; Zinman L; Parker JA; Legault P; Tétreault M; Barmada SJ; Robertson J; Vande Velde C
Brain; 2021 Dec; 144(11):3461-3476. PubMed ID: 34115105
[TBL] [Abstract][Full Text] [Related]
9. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.
Scotter EL; Chen HJ; Shaw CE
Neurotherapeutics; 2015 Apr; 12(2):352-63. PubMed ID: 25652699
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD.
Fang MY; Markmiller S; Vu AQ; Javaherian A; Dowdle WE; Jolivet P; Bushway PJ; Castello NA; Baral A; Chan MY; Linsley JW; Linsley D; Mercola M; Finkbeiner S; Lecuyer E; Lewcock JW; Yeo GW
Neuron; 2019 Sep; 103(5):802-819.e11. PubMed ID: 31272829
[TBL] [Abstract][Full Text] [Related]
11. Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy.
Khalil B; Chhangani D; Wren MC; Smith CL; Lee JH; Li X; Puttinger C; Tsai CW; Fortin G; Morderer D; Gao J; Liu F; Lim CK; Chen J; Chou CC; Croft CL; Gleixner AM; Donnelly CJ; Golde TE; Petrucelli L; Oskarsson B; Dickson DW; Zhang K; Shorter J; Yoshimura SH; Barmada SJ; Rincon-Limas DE; Rossoll W
Mol Neurodegener; 2022 Dec; 17(1):80. PubMed ID: 36482422
[TBL] [Abstract][Full Text] [Related]
12. TDP-43 pathology: From noxious assembly to therapeutic removal.
Keating SS; San Gil R; Swanson MEV; Scotter EL; Walker AK
Prog Neurobiol; 2022 Apr; 211():102229. PubMed ID: 35101542
[TBL] [Abstract][Full Text] [Related]
13. Mislocalization of Nup62 Contributes to TDP-43 Proteinopathy in ALS/FTLD.
Nag N; Tripathi T
ACS Chem Neurosci; 2022 Sep; 13(17):2544-2546. PubMed ID: 36001801
[TBL] [Abstract][Full Text] [Related]
14. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy.
Chen HJ; Topp SD; Hui HS; Zacco E; Katarya M; McLoughlin C; King A; Smith BN; Troakes C; Pastore A; Shaw CE
Brain; 2019 Dec; 142(12):3753-3770. PubMed ID: 31605140
[TBL] [Abstract][Full Text] [Related]
15. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.
Montalbano M; McAllen S; Cascio FL; Sengupta U; Garcia S; Bhatt N; Ellsworth A; Heidelman EA; Johnson OD; Doskocil S; Kayed R
Neurobiol Dis; 2020 Dec; 146():105130. PubMed ID: 33065281
[TBL] [Abstract][Full Text] [Related]
16. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
Vanden Broeck L; Callaerts P; Dermaut B
Trends Mol Med; 2014 Feb; 20(2):66-71. PubMed ID: 24355761
[TBL] [Abstract][Full Text] [Related]
17. Aggresome formation and liquid-liquid phase separation independently induce cytoplasmic aggregation of TAR DNA-binding protein 43.
Watanabe S; Inami H; Oiwa K; Murata Y; Sakai S; Komine O; Sobue A; Iguchi Y; Katsuno M; Yamanaka K
Cell Death Dis; 2020 Oct; 11(10):909. PubMed ID: 33097688
[TBL] [Abstract][Full Text] [Related]
18. S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD.
Pirie E; Oh CK; Zhang X; Han X; Cieplak P; Scott HR; Deal AK; Ghatak S; Martinez FJ; Yeo GW; Yates JR; Nakamura T; Lipton SA
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33692125
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding proteins with prion-like domains in health and disease.
Harrison AF; Shorter J
Biochem J; 2017 Apr; 474(8):1417-1438. PubMed ID: 28389532
[TBL] [Abstract][Full Text] [Related]
20. TDP-43 aggregation in neurodegeneration: are stress granules the key?
Dewey CM; Cenik B; Sephton CF; Johnson BA; Herz J; Yu G
Brain Res; 2012 Jun; 1462():16-25. PubMed ID: 22405725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
